These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22721367)

  • 1. [Pharmacological treatment of spasticity in multiple sclerosis].
    Heinzlef O; Monteil-Roch I
    Rev Neurol (Paris); 2012 Apr; 168 Suppl 3():S62-8. PubMed ID: 22721367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
    Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacology and upper limb poststroke spasticity: a review. International Society of Prosthetics and Orthotics].
    Yelnik AP
    Ann Readapt Med Phys; 2004 Oct; 47(8):575-89. PubMed ID: 15465163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic interventions for reducing spasticity in cerebral palsy.
    Patel DR; Soyode O
    Indian J Pediatr; 2005 Oct; 72(10):869-72. PubMed ID: 16272661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal Baclofen Infusion-Botulinum Toxin Combined Treatment Efficacy in the Management of Spasticity due to Cerebral Palsy.
    Marvulli R; Lagioia G; Ianieri G; Dell'Olio L; Zonno A; Riccardi M; Sinisi RB; Rizzo LB; Farì G; Megna M; Ranieri M
    CNS Neurol Disord Drug Targets; 2024; 23(7):917-926. PubMed ID: 38213169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
    Schapiro RT
    Curr Neurol Neurosci Rep; 2001 May; 1(3):299-302. PubMed ID: 11898533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing spasticity with drugs.
    Simon O; Yelnik AP
    Eur J Phys Rehabil Med; 2010 Sep; 46(3):401-10. PubMed ID: 20927006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mixed treatment comparison on efficacy and safety of treatments for spasticity caused by multiple sclerosis: a systematic review and network meta-analysis.
    Fu X; Wang Y; Wang C; Wu H; Li J; Li M; Ma Q; Yang W
    Clin Rehabil; 2018 Jun; 32(6):713-721. PubMed ID: 29582713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of spasticity].
    Autti-Rämö I
    Duodecim; 1999; 115(8):877-85. PubMed ID: 11859520
    [No Abstract]   [Full Text] [Related]  

  • 11. Intrathecal baclofen for muscle spasticity and pain--two case reports.
    Al Khudhairi D; Rababa A; Saddiqui MN
    Middle East J Anaesthesiol; 2006 Jun; 18(5):971-6. PubMed ID: 17094537
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs used to treat spasticity.
    Kita M; Goodkin DE
    Drugs; 2000 Mar; 59(3):487-95. PubMed ID: 10776831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice parameter: pharmacologic treatment of spasticity in children and adolescents with cerebral palsy (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.
    ; Delgado MR; Hirtz D; Aisen M; Ashwal S; Fehlings DL; McLaughlin J; Morrison LA; Shrader MW; Tilton A; Vargus-Adams J
    Neurology; 2010 Jan; 74(4):336-43. PubMed ID: 20101040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study.
    Middleton JW; Siddall PJ; Walker S; Molloy AR; Rutkowski SB
    Arch Phys Med Rehabil; 1996 Aug; 77(8):824-6. PubMed ID: 8702379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal baclofen for spasticity management: a comparative analysis of spasticity of spinal vs cortical origin.
    Saval A; Chiodo AE
    J Spinal Cord Med; 2010; 33(1):16-21. PubMed ID: 20397440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacology of spasticity. Does therapy remain in deep sleep?].
    Noth J
    Nervenarzt; 2000 Dec; 71(12):927-8. PubMed ID: 11139987
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacologic treatment of spasticity in children.
    Tilton A; Vargus-Adams J; Delgado MR
    Semin Pediatr Neurol; 2010 Dec; 17(4):261-7. PubMed ID: 21183133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathogenetic therapy of spasticity].
    Kasatkin DS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):80-5. PubMed ID: 18697257
    [No Abstract]   [Full Text] [Related]  

  • 19. A double-blind comparative trial of new muscle relaxant, tizanidine (DS 103-282), and baclofen in the treatment of chronic spasticity in multiple sclerosis.
    Smolenski C; Muff S; Smolenski-Kautz S
    Curr Med Res Opin; 1981; 7(6):374-83. PubMed ID: 7016449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intrathecal baclofen in severe spasticity due to multiple sclerosis].
    Sławek J; Zieliński P; Hołub-Kucharska W; Kaniszewska J; Paczkowska M; Słoniewski P
    Neurol Neurochir Pol; 2003; 37(5):1135-42; discussion 1143. PubMed ID: 15174259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.